关闭
 
读者在线:用户名 密码
首页 期刊简介 投稿须知 期刊目录 专家风采 编委会 特邀顾问 联系我们 移动出版
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5



刊物信息

期刊名称:药物分析杂志
主管单位:中国科学技术协会
主办单位:中国药学会
承办:中国食品药品检定研究院
主编:金少鸿
地址:北京天坛西里2号
邮政编码:100050
电话:010-67012819,67058427
电子邮箱:ywfx@nifdc.org.cn
国际标准刊号:ISSN 0254-1793
国内统一刊号:CN 11-2224/R
邮发代号:2-237
 

访问统计
您是第  1 2 3 2 3 3 1 2 位浏览者
您当前的位置:首页 >> 正文

艾司唑仑片溶出数据的Weibull分布

Weibull distribution of dissolution data of estazolam tablets

分类号:
出版年·卷·期(页码):2016,36 (6):0-0
DOI: 10.16155/j.0254-1793.2017.01.01
-----摘要:-------------------------------------------------------------------------------------------

目的: 使用Weibull 分布模型拟合艾司唑仑片的溶出曲线,通过比较6 条曲线参数来评价制备工艺,并为评价艾司唑仑体外溶出行为提供新的方法。方法: 利用DDSolver 软件分别对来自市场抽验的6 个不同厂家的样品进行溶出数据拟合。以自制样品G 为参比,利用OriginPro 8.0 对各参数进行双侧t-检验。结果: 与样品G 进行比较,由t-检验结果发现:样品B 仅Td 值表现出明显差异;样品A 的T50Td 值均有明显差异;而样品D 除了T50Td 值外,形状参数β 也表现出了明显差异;C、E、F 3 批样品除了位置参数Ti 外,其余各参数均有明显差异。结论: 每批样品需要达到较高的溶出速率才能使溶出曲线与样品G 一致。因此,样品A 通过优化粒径,样品D 经过优化工艺参数和辅料,均可以获得较高的溶出速率;而C、E、F 3 批样品要想达到此目的有点困难,需对工艺参数和处方进行改进。

-----英文摘要:---------------------------------------------------------------------------------------

Objective: To evaluate the producing process by comparing the parameters of six profiles through fitting dissolution profiles of estazolam tablets with Weibull distribution model,so as to provide a new method for evaluating estazolam tablets in vitro dissolution behavior. Methods: Respectively,the profiles of estazolam tablets samples from 6 different manufacturers were fitted by DDSolver software. Taking the homemade sample G as the reference product,the parameters were tested by the bilateral t-test using OriginPro 8.0.Results: According to t-test results,compared with product G,there was no statistical difference in all parameters of sample B except Td;while the T50 and Td of sample A were significantly different. Furthermore,the shape parameter βof sample D showed a significant difference besides T50 and Td,while all other parameters of samples C,E and F exhibited obvious difference except Ti. Conclusion: Each sample needs a higher dissolution rate to make its dissolution profile consistent with sample G. To achieve this purpose,sample A should be optimized at the particle size,sample D should be improved at both process parameters and excipients;however,the other three samples are difficult to achieve the purpose as both process parameters and prescription need to be improved.

-----参考文献:---------------------------------------------------------------------------------------

欢迎阅读《药物分析杂志》!您是该文第 743位读者!

药物分析杂志 © 2009
地址:北京天坛西里2号 邮政编码:100050; 电子邮件:ywfx@nicpbp.org.cn